A high percentage of cancer drugs may never advance beyond the first phase. How can you boost the chances that yours will beat the odds and have a better chance of success?
September 30, 2020
Flow Cytometry User Groups And The Relaunch Of The NWFCS
By Jennifer J. Stewart, PhD
Live Dead Measurement and Cell Viability
By Marrisssa Bailey, BS
To Fc or not Fc: An assay for the question
By Shalina Prasad BS
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
